Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Cereno Scientific’s innovative study design of the Phase II study of CS1 in PAH published in renowned journal Pulmonary Circulation

Cereno Scientific (Nasdaq First North: CRNO B), a company developing innovative treatments for common and rare cardiovascular disease, today announced that a research article on the innovative study design of the ongoing Phase II study of drug candidate CS1 in pulmonary arterial hypertension (PAH) has been published in the renowned medical journal Pulmonary Circulation.The research article describes how the design of clinical trials is important to fully understand the mechanisms and benefits of new treatments. Numerous potential pharmacological treatments for PAH have shown promise in

BioStock Investor Pitch: Oncoinvent

Oncoinvent’s CEO Anders Månsson visited BioStock’s studio to talk about the development of the radiopharmaceutical Radspherin for peritoneal carcinomatosis. In his presentation, he delves into the results from the phase I/IIa studies with Radspherin and the upcoming clinical development plan. Furthermore, he talks about Oncoinvent as an investment opportunity and the unmet medical need for these cancer patients.Watch Anders Månsson present Oncoinvent at biostock.se : https://www.biostock.se/en/2024/01/biostock-investor-pitch-oncoinvent/ This is a press

Bioretec Ltd – Managers’ transactions

Bioretec Ltd      Managers’ transactions 5 January 2024 at 11.00 a.m. EETBioretec Oy - Managers' Transactions __________________________________________ Person subject to the notification requirement Name: Stephen Industries Inc Oy Position: Closely associated person (X) Legal person  (1):Person Discharging Managerial Responsibilities In Issuer Name: Kustaa Poutiainen Position: Member of the Board Issuer: Bioretec Oy LEI: 7437008736AG7HY51K13 Notification type: INITIAL NOTIFICATION Reference number: 48652/4/6 ____________________________________________

Allgon opens a new office in Denmark

Gothenburg, January 5th, 2024. Further increasing its worldwide position in the industrial wireless communication field, Allgon announces the opening of the new Tele Radio subsidiary in Denmark. The company, Tele Radio Denmark ApS based in Svenstrup, is the 26th subsidiary that has opened its doors, giving Allgon Group presence in now 23 countries. The branch officially began operations in December 1st, 2023.Helene Kyo Johansen is leading Tele Radio Denmark as its General Manager and Sales Manager. Helene has a successful 13-year trajectory as product manager in Tele Radio’s sister

ZINZINO AB (PUBL): PRELIMINARY SALES REPORT 2023

Zinzino group total revenue increased 23% in Q4 and total revenue for the full year 2023 increased 23%, compared to the previous year. The revenue in December for Zinzino's sales markets increased by 23 % and amounted to SEK 152.4 (123.8) million. Faun Pharma's external sales decreased and amounted to SEK 5.0 (5.1) million. Overall, the Group increased revenues by 22% to SEK 157.4 (128.9) million compared with the previous year. Sales in Zinzino's sales markets increased by 24% in the fourth quarter of 2023 compared with the same period last year and amounted to SEK 511.2 (413.3)

Notification of managers’ and closely related parties’ transactions with Dampskibsselskabet NORDEN A/S’ shares in connection with share buy-back program

ANNOUNCEMENT NO. 5 - 5 JANUARY 2024   In connection with the announced share buy-back program in NORDEN, A/S Motortramp continuously sells shares pro rata and the market is to be informed accordingly – see the attached file and announcements nos. 186/23 and 187/23.   Kind regards, Dampskibsselskabet NORDEN A/S   Martin Badsted CFO     For further information: Stig Frederiksen, Head of Investor Relations, tel.: +45 32 71 08 55, e-mail: sfr@norden.com

Dicot invited to present at ESSM for the third time

Press release: Uppsala, Sweden, January 5, 2024. The pharmaceutical company Dicot's preclinical research results have been selected to be presented at the European Society for Sexual Medicine's conference in February. It is the third year in a row that Dicot will present at Europe's largest event in the field of sexual medicine.The European Society for Sexual Medicine (ESSM) is Europe's leading scientific organization in sexual medicine whose annual conference brings together prominent researchers and doctors from all over the world. The ESSM Scientific Council has selected Dicot's

Konecranes to modernize two cranes for Fortum Power & Heat at Finland’s largest hydropower plant

Photo: Fortum Power & HeatKonecranes will modernize the industrial cranes at Fortum Power & Heat’s turbine hall in Imatra, Finland to ensure a continued steady supply of electricity for over 50,000 households annually. The order was booked in November 2023, with deliveries and installation scheduled for October 2024. The modernization of the two aging cranes at the Imatra Hydropower Plant, which started operations in 1929, will enhance performance and extend the cranes' service life. The project involves working within the confines of a protected historical building, adding

Volvo Cars reports new global sales record in 2023

Volvo Cars sets a new global sales record as the company reports full year sales of 708,716 cars during 2023, an increase of 15 per cent compared to the full year of 2022.The all-time-high sales record is a demonstration of Volvo Cars’ strong electrified product portfolio in combination with a more stabilised supply chain.   Volvo Cars also saw a significant increase in sales for its electrified cars. Last year, Volvo Cars sold 113,419 fully electric cars, an increase of 70 per cent compared to 2022, and 152,561 plug-in hybrid cars, which was a 10 per cent increase compared to 2022.

Aptahem receives Notice of Allowance in Israel for patent family 2

Aptahem AB (publ) announces today that the company has received a Notice of Allowance in Israel of the patent application no 273759 entitled A nucleic acid molecule with anti-inflammatory and anti-coagulant and organ-protective properties.The notice of allowance is a formal communication from the patent authority in which it indicates that the patent application has reached the status where it is allowed for issuance as a patent. When issued, the patent will be valid until, and including, 2038. CEO Mikael Lindstam comments: ”I am very pleased to receive the news that yet another

Repurchase of Outokumpu’s own shares

Outokumpu OyjStock exchange releaseJanuary 5, 2024 at 9.30 am EETRepurchase of Outokumpu’s own shares On January 4, 2024, Outokumpu has completed repurchases of its own shares as follows (ISIN FI0009002422): +-------+----------------+------------------------------------+----------------+|Trading|Number of shares|Weighted average price / share, EUR*|Total cost, EUR*||venue | | | |+-------+----------------+------------------------------------+----------------+|CEUX |87,216 |4.2083

NYAB Oyj - Managers' Transactions

NYAB PlcMANAGERS' TRANSACTIONS05 January 2024 at 09:30NYAB Oyj - Managers' Transactions____________________________________________Person subject to the notification requirementName: BINGAB Barents Investment Group ABPosition: Closely associated person(X) Legal person (1):Person Discharging Managerial Responsibilities In IssuerName: Johan LarssonPosition: Chief Executive OfficerIssuer: NYAB OyjLEI: 743700UX7WTIOT3QO547Notification type: INITIAL NOTIFICATIONReference number: 48650/4/6 ____________________________________________Transaction date: 2024-01-02

Insider information, profit warning: Net sales growth in 2023 stays slightly below the guidance, operating profit margin at guidance high end or above

Qt Group Plc, stock exchange release, January 5, 2024 at 9:15am EETAccording to preliminary figures which have not been audited, Qt Group Plc’s net sales in the last quarter of 2023 will be approximately EUR 59 million. Our full-year net sales for 2023 will be approximately EUR 180-181 million. Thus, the net sales growth at comparable exchange rates will be approximately 18-19 % in 2023 year-on-year. The company estimates the operating profit margin (EBITA-%) to be close to 30 % or slightly above in 2023.  According to the company’s guidance, released on October 26, 2023, our full-

Metso to deliver key crushing equipment for the Simandou iron ore project in Guinea

Metso Corporation’s press release on January 5, 2024, at 09:00 a.m. EETMetso has received an order from Winning Consortium Simandou (WCS) for the supply of key crushing equipment for their concentrator plant at Simandou Iron Ore Blocks 1 and 2 in the Republic of Guinea. The value of the order exceeds EUR 10 million, and it is booked in Minerals’ 2023 fourth-quarter order intake. Metso’s scope of delivery consists of 16 Nordberg® HP900™ secondary and tertiary cone crushers. Metso’s Nordberg® HP Series has over 10,000 installations worldwide in the aggregate and mining industries. “We

Oneflow’s monthly ARR update: December 2023

Press release5 January 2024 Oneflow publishes its preliminary monthly ARR. Oneflow had a total ARR (Annual Recurring Revenue) of MSEK 129.3 by the end of December 2023. This is a preliminary number. All financial reports and presentations are available for download on our website here: https://oneflow.com/ir/investors/financial-reports/ For further information, please contact: Anders Hamnes, CEO and FounderMobile: +46 76 788 50 76Email: anders.hamnes@oneflow.com Certified Adviser is FNCA Sweden AB. About Oneflow Oneflow develops, sells, and implements digital

Finnair Traffic Performance in December 2023

Finnair Plc                Investor News              5 January 2024 at 9:00 a.m. EET Increase in passenger traffic numbers year-on-year and month-on-month, on-time performance impacted by severe weather conditions In December, Finnair carried 878,200 passengers, which was 5.4% more than in December 2022 and 8.2% more than in November 2023. Month-on-month figures are not fully comparable as there was one day less in November. December passenger traffic figures improved year-on-year as the COVID-19 pandemic impacts have mostly faded and as the Russian airspace was closed during the

Transaction in Own Shares

    05 January 2024 Vesuvius plc Share Buyback Programme – Transactions in Own Securities   Vesuvius plc (the "Company") announces that it has purchased the following number of its Ordinary Shares of 10p each from Jefferies International Limited (the “Broker”), pursuant to the terms of its Share Buyback Programme announced on 4 December 2023:   +---------------------------------------------------------------+----------+|Date of purchase: |04/01/2024|+-----------------------------------------------------------

Sobi’s Chairman of the Board resigns due to health reasons

Swedish Orphan Biovitrum AB’s (publ) (Sobi®) (STO: SOBI) (“Sobi”) Chairman of the Board Bo Jesper Hansen resigns, at his own request and with immediate effect, from his position as Chairman of the Board and board member due to health reasons.Bo Jesper Hansen has been deputy Chairman of the Board of Sobi since the annual general meeting in May 2022 and Chairman of the Board of Sobi since the annual general meeting in May 2023. Annette Clancy assumes with immediate effect the role of Chair of the Board. Annette has been a board member of Sobi since 2014 and has extensive experience from

UNION therapeutics to present at the 42nd Annual J.P. Morgan Healthcare Conference

Hellerup, Denmark, January 5, 2024 – UNION therapeutics A/S (UNION), a privately held, clinical stage, pharmaceutical development company focused on immunology, today announced that Dr. Kim Kjøller, CEO of UNION will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8-11, 2024, in San Francisco, US.  Dr. Kjøller will be presenting at 11:00am PST on Monday, January 8, 2024, and will provide an update on the business with emphasis on key achievements and current status of the lead program orismilast, a potent selective PDE4 B/D inhibitor, currently in development

Stirling Square, TA and Macquarie Capital, through Giant BidCo, announce a recommended public cash offer of SEK 46 to the shareholders of Byggfakta

THIS PRESS RELEASE IS NOT AN OFFER, WHETHER DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND OR SOUTH AFRICA OR IN ANY OTHER JURISDICTION WHERE SUCH OFFER PURSUANT TO LEGISLATION AND REGULATIONS IN SUCH RELEVANT JURISDICTION WOULD BE PROHIBITED. SHAREHOLDERS NOT RESIDENT IN SWEDEN WHO WISH TO ACCEPT THE OFFER (AS DEFINED BELOW) MUST MAKE INQUIRIES CONCERNING APPLICABLE LEGISLATION AND POSSIBLE TAX CONSEQUENCES. SHAREHOLDERS SHOULD REFER TO THE OFFER RESTRICTIONS INCLUDED IN THE SECTION TITLED “IMPORTANT INFORMATION” AT THE END OF THIS PRESS RELEASE AND IN THE

Lea bank ASA - Notice of Extraordinary General Meeting

Lea bank’s shareholders are hereby given notice of an extraordinary general meeting to be held on January 22 2024, at 10:00 AM CET (the “EGM”) at the bank's offices at Holbergs gate 21, 0166 Oslo. Please see attached notice of the EGM. The notice will be sent electronically or by mail to all shareholders with a known address. The notice and other documents related to the agenda are also available at leabank.no/about-us/investor-relations/general-meeting Contact Information: Oddbjørn Berentsen, CEO Phone: +47 22 99 14 00 Email: ir@leabank.no

Nanoform Commenced Relative Bioavailability Study of Nanotechnology-Enhanced Enzalutamide

Press release Nanoform Finland Plc January 5, 2023 08:10 Finnish time / 07:10 Swedish time Nanoform Commenced Relative Bioavailability Study of Nanotechnology-Enhanced Enzalutamide Helsinki, Finland – Nanoform Finland Plc (“Nanoform”), the medicine performance enhancing company, today announced it had completed the First Subject First Visit (FSFV) in a trial to evaluate the relative bioavailability of its nanocrystalline enabled alternative; to an amorphous solid dispersion (ASD);formulation of nanoenzalutamide and Xtandi[®[1]], the number one prescribed androgen receptor

Nordea Bank Abp: Repurchase of own shares on 04.01.2024

Nordea Bank AbpStock exchange release – Changes in company’s own shares04.01.2024 at 22.30 EET Nordea Bank Abp (LEI: 529900ODI3047E2LIV03) has on 04.01.2024 completed repurchases of own shares (ISIN: FI4000297767) as follows: +----------+-------+-------------------+-------------------+| Trading |Number | Weighted average |Total cost, EUR* **||venue (MIC| of |price / share, EUR*| || Code) |shares | ** | |+----------+-------+-------------------+-------------------+|XHEL |47,051 |11.40 |536,188.49

Bioservo to be delisted from Nasdaq First North

Nasdaq has decided to approve Bioservo Technologies' application to delist its shares (short name BIOS, ISIN code SE0009779085) from Nasdaq First North Growth Market. The last day of trading on Nasdaq First North Growth Market is January 11, 2024. For more information, please contactLawyer Olov Kling, liquidator, Konrad Advokater ABphone: +46 70 210 13 79olov.kling@konradadvokater.se Mikael Wester, Marketing Director, Bioservo Technologies ABphone: +468 21 17 10mikael.wester@bioservo.com  About Bioservo TechnologiesBioservo Technologies AB (publ) is a world leading

There are no items matching the current filter
There are no more items matching the current filter
Back to top